A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
Researchers at Stanford have developed practical applications that use germline information (e.g., germline epitope burden) for diagnosis, monitoring and treatment of cancer.
Researchers at Stanford have created ligand-induced dimerization activating RNA editing (LIDAR), a versatile molecular sensor that turns the presence of a ligand into translation of an output protein.
The potency of cancer immunotherapies for solid tumors are often diminished by inadequate metabolic reprogramming and resulting immune evasion in cancer.
Researchers in the Mackall lab at Stanford have developed an adoptive cell therapy modification that enhances anti-tumor activity by disrupting a specific group of genes.
Researchers in the Sunwoo Lab have developed a method to differentiate intra-epithelial innate lymphoid cells type 1 (ieILC1s) from conventional peripheral natural kills cells for immunotherapeutic purposes.
Researchers at Stanford have developed chimeric antigen receptors (CARs) that target glypican-2 (GPC2) and can be used to treat solid tumors. CAR-engineered T cells have shown great promise as cancer therapeutics.
Researchers at Stanford have developed methods to classify and treat MYC-driven hematopoietic cancers. The MYC oncogene drives the proliferation and survival of many hematopoietic cancers. These cancers are highly aggressive and do not respond to conventional chemotherapies.
Stanford researchers have developed a method that can tune the ratio between reversible (RE) and irreversible (IRE) electroporation through waveform adjustments.